This is the third IND candidate from Astex’s internal discovery and development programmes to be approved. Astex plans to begin clinical trials of AT13387 in cancer patients during 2008.
Harren Jhoti, CEO of Astex, said: “This approval is a great achievement and a testament to the productivity of our fragment-based drug discovery platform and keeps us on target to deliver at least one IND candidate per year.”